Vera Therapeutics, INC Form 4 insider transactions

Marshall Fordyce, PRESIDENT AND CEO and a Director of Vera Therapeutics, Inc., sold 46,250 shares of common stock on July 7, 2026.

Marshall Fordyce, PRESIDENT AND CEO and a Director of Vera Therapeutics, Inc., sold 18,500 shares of common stock on June 23, 2026.

Marshall Fordyce, PRESIDENT AND CEO and a Director of Vera Therapeutics, Inc., sold 18,500 shares of common stock on May 12, 2026.

Vera Therapeutics President and CEO, Marshall Fordyce, reported the sale of over 46,000 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Vera Therapeutics President and CEO Marshall Fordyce sold a significant number of Class A Common Stock shares under a pre-arranged trading plan.

Vera Therapeutics Director Scott W. Morrison was granted stock options for 17,084 shares of Class A Common Stock.

Andrew Cheng, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 20, 2036, or earlier upon a change in control.

Beth C. Seidenberg, a Director at Vera Therapeutics, Inc., acquired stock options for 17,084 shares of Class A Common Stock.

Vera Therapeutics Director Christy J. Oliger acquired 17,084 stock options with an exercise price of $34.35, vesting under specific conditions related to service and company events.

James R. Meyers, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 20, 2036, or earlier upon a change in control.

Vera Therapeutics Director Kimball Hall acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 21, 2027, or upon a change in control.

Michael Morrissey, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting under specific conditions.

Vera Therapeutics, Inc. reports that Director Patrick G. Enright acquired stock options on May 21, 2026, as detailed in a Form 4 filing.

Vera Therapeutics President and CEO Marshall Fordyce sold a significant number of Class A Common Stock shares under a pre-arranged trading plan.

President and CEO Marshall Fordyce sold 22,951 shares of Vera Therapeutics common stock under a pre-arranged 10b5-1 trading plan.

Vera Therapeutics' Chief Legal Officer, Jane Wright-Mitchell, received grants of 42,403 restricted stock units and options to purchase 56,850 shares of Class A Common Stock.

Vera Therapeutics' SVP of Finance and Chief Accounting Officer, Joseph R. Young, acquired 10,000 shares of Class A Common Stock through an option exercise and additional shares via an Employee Stock Purchase Plan.

Vera Therapeutics' Chief Medical Officer, Robert Brenner, sold 2,151 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

A Vera Therapeutics executive sold 3,117 shares of Class A Common Stock to cover tax withholding obligations from RSU vesting.

Vera Therapeutics' Chief Financial Officer, Sean Grant, sold 4,949 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Vera Therapeutics President and CEO Marshall Fordyce sold 16,925 shares of Class A Common Stock to cover tax withholding obligations from RSU vesting.

Vera Therapeutics' Chief Operating Officer, David Lee Johnson, sold 2,579 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, sold 2,187 shares of Class A Common Stock to cover tax withholding obligations from RSU vesting.

Vera Therapeutics' Chief Commercial Officer, Laurence Matthew Skelton, sold 1,582 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Joseph R. Young, SVP of Finance and Chief Accounting Officer at Vera Therapeutics, received 10,000 restricted stock units and options for 20,000 shares.

Vera Therapeutics' President and CEO, Marshall Fordyce, reported significant equity awards including restricted stock units and stock options, alongside a transfer of shares to a trust.

Vera Therapeutics' Chief Financial Officer, Sean Grant, received significant equity grants, including 25,000 restricted stock units and options for 50,000 shares, signaling increased long-term alignment.

Vera Therapeutics' Chief Commercial Officer, Laurence Matthew Skelton, was granted 20,000 restricted stock units and options to purchase 40,000 shares of Class A Common Stock.

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, was granted 25,000 restricted stock units and options to purchase 50,000 shares of Class A Common Stock.

Vera Therapeutics' Chief Operating Officer, David Lee Johnson, was granted 20,000 restricted stock units and 40,000 stock options as part of a pre-planned equity incentive.